Physician- Pediatric Hematology​/Oncology Hospitalist Nocturnist

Note:

If you are CURRENTLY employed at Children's and/or have an active badge or network access, STOP here. Submit your application via Workday using the Career App (Find Jobs).

Regular

Children’s is one of the nation’s leading children’s hospitals. No matter the role, every member of our team is an essential part of our mission to make kids better today and healthier tomorrow. We’re committed to putting you first, and that commitment is at the heart of our company culture:
People first. Children always. Find your next career opportunity and make a difference doing what you love at Children’s.

To plan, implement and evaluate the provision of high-quality medical care, with appropriate resource management, to children and adolescents in Aflac Cancer & Blood Disorders Center.

The Aflac Cancer & Blood Disorders Center of Children’s Healthcare of Atlanta and the Emory University Department of Pediatrics invites interested applicants for a faculty level position in pediatric Hematology Oncology. The Aflac Cancer & Blood Disorders Center provides a rich and collaborative environment for basic, clinical, and translational research and boasts a diverse faculty. These physicians will care for hematology and oncology patients during the night, including patients receiving chemotherapy.

Our nocturnists work collaboratively with residents and other specialists to admit children requiring hematology/oncology care, take nurse calls, offering after-hours expertise in managing the complex illnesses that children with cancer and blood disorders develop.

Our nocturnists staff the Aflac Cancer and Blood Disorders Center inpatient units for 13 hours a day, seven days a week. This position will devote effort to inpatient clinical responsibilities from 6:30PM to 7:30AM for a total of 114 shifts/year.

This position is located at Arthur M. Blank Hospital.

Qualified candidates should be Board Certified/Eligible Pediatricians, and preference will be given to applicants with Hematology/Oncology training/experience.

The successful candidate will join one of the strongest pediatric hematology/oncology programs in the country.

• In 2024, the Aflac Cancer & Blood Disorders Center was ranked No. 12 in the nation for Pediatric Cancer by US News and World Report
• Each year our team cares for more than 170 newly diagnosed leukemia and lymphoma patients using a variety of treatment protocols, including blood and marrow transplant (BMT), hematopoietic stem cell transplant, chimeric antigen receptor (CAR)-T therapy, and Phase I and II clinical trials for patients whose cancer has relapsed or is not responding to treatment
• The Aflac Cancer & Blood Disorders Center has over 130 faculty and nearly 50 Advance Practice Providers (APPs), conducting basic, translational, cooperative group and investigator-initiated clinical research related to pediatric oncology and hematology disorders, with expertise in leukemias, lymphomas, brain tumors, neuroblastoma, sarcomas, rare tumors, renal tumors, CAR T-cell therapies, cancer survivorship, health services research, hemoglobinopathies and hemophilia.
• More than 9,000 children with cancer and blood disorders are treated annually at the Aflac Cancer & Blood Disorders Center
• The Aflac pediatric oncology program sees 500 new cancer diagnoses each year. Aflac is the pediatric component of the Winship Cancer Institute of Emory University.
• The Aflac pediatric hematology program is one of the largest in the country (including >2,000 active patients with sickle cell disease, and >1,000 with bleeding or clotting disorders)
• The Aflac blood and marrow transplantation program performs 80 transplants each year, and is one of the leaders in curative therapies for hemoglobinopathies.
• In 2024, Aflac faculty generated $31M in extramural funding, including more than $17M from the NIH
• The Aflac fellowship program accepts 6 fellows each year for intensive clinical and research training in pediatric hematology/oncology. We are one of the few pediatric programs with an NIH-funded T32 training grant in…